InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026)
InflaRx (IFRX) posted Total Non-Current Liabilities of $712532.2 for Q1 2026, down 9.7% sequentially from $789046.9 in Q4 2025, and up 103.83% YoY from $349563.3 in Q1 2025.
InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
InflaRx has reported Total Non-Current Liabilities for 11 years, with the latest figure at $712532.2 in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 103.83% year-over-year to $712532.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $712532.2 (up 103.83% YoY) and the FY2025 annual result came in at $765842.5, up 62.31% from the prior year.
- Total Non-Current Liabilities eased to $712532.2 in Q1 2026 per IFRX's latest filing, from $789046.9 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.3 million in Q2 2022 and troughed at $272525.0 in Q2 2025.
- A 5-year average of $811990.8 and a median of $842023.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 446.31% in 2022, then slumped 60.34% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $1.0 million in 2022, then dropped by 19.42% to $842023.0 in 2023, then sank by 44.68% to $465846.7 in 2024, then surged by 69.38% to $789046.9 in 2025, then dropped by 9.7% to $712532.2 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $712532.2, $789046.9, and $861618.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 694,361.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 712,532.19 |
| Dec 31, 2025 | 789,046.90 |
| Sep 30, 2025 | 861,618.15 |
| Jun 30, 2025 | 272,524.95 |
| Mar 31, 2025 | 349,563.29 |
| Dec 31, 2024 | 465,846.68 |
| Sep 30, 2024 | 588,431.50 |
| Jun 30, 2024 | 687,131.81 |
| Mar 31, 2024 | 829,909.78 |
| Dec 31, 2023 | 842,023.04 |
| Sep 30, 2023 | 880,333.32 |
| Jun 30, 2023 | 927,150.52 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.13 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.40 Mn |
| Jun 30, 2021 | 1.54 Mn |